- Global Pharma News & Resources

Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018 -

The "Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018" drug pipelines has been added to's offering.

Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 108, 67, 1, 9, 160, 28 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 11, 15, 1, 43 and 10 molecules, respectively.

Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Companies Featured

  • AbbVie Inc
  • Actuate Therapeutics Inc
  • APIM Therapeutics AS
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Co
  • Caladrius Biosciences Inc
  • Celldex Therapeutics Inc
  • DNAtrix Inc
  • Dr. Reddy's Laboratories Ltd
  • Ecrins Therapeutics SAS
  • Eisai Co Ltd
  • Eli Lilly and Co
  • F-star Biotechnology Ltd
  • Hamlet Pharma AB
  • ImmunoCellular Therapeutics Ltd
  • Immunomedics Inc
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • Kadmon Corp LLC
  • Kancera AB
  • Merck KGaA
  • MetaMax Ltd
  • Midatech Pharma Plc
  • Oncternal Therapeutics Inc
  • Peloton Therapeutics Inc
  • Peptomyc SL
  • Pfizer Inc
  • ReNeuron Group Plc
  • Rgenix Inc
  • Richter Gedeon Nyrt
  • Sanofi
  • Taiho Pharmaceutical Co Ltd
  • Terpenoid Therapeutics Inc
  • and many, many more...

For more information about this drug pipelines report visit

View source version on

Editor Details

Last Updated: 19-Oct-2018